Welcome to our dedicated page for Ardelyx news (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.
Ardelyx, Inc. develops and commercializes biopharmaceutical products built around tenapanor and NHE3 inhibition. The company has two U.S.-approved commercial products: IBSRELA for adults with irritable bowel syndrome with constipation and XPHOZAH to reduce serum phosphorus in adults with chronic kidney disease on dialysis when phosphate binder therapy is inadequate or not tolerated.
Ardelyx news commonly covers product revenue, prescription trends, business updates, scientific meeting presentations, and clinical analyses tied to XPHOZAH and IBSRELA. Recurring developments also include pipeline work in chronic idiopathic constipation and next-generation NHE3 inhibition, commercialization with partners outside the United States, patient advocacy programs, and executive leadership changes in medical, legal, finance, and compliance functions.
Ardelyx, Inc. (Nasdaq: ARDX) will present additional data supporting IBSRELA® (tenapanor) for adults with irritable bowel syndrome with constipation at the 2024 Digestive Disease Week Conference. IBSRELA is approved by the FDA to treat IBS-C in adults. The presentation will include posthoc analysis from Phase 3 studies and a Product Theater discussing clinical considerations for managing IBS-C.
Ardelyx, Inc. (Nasdaq: ARDX) reported $45.6 million in Q1 product-related revenue, with $28.4 million from IBSRELA and $15.2 million from XPHOZAH. The company ended Q1 with around $203 million in cash and investments. Ardelyx saw significant growth in net product sales revenue for both IBSRELA and XPHOZAH, with plans to expand market position. The company appointed Mike Kelliher as EVP, Corporate Development and Strategy. Total revenue for Q1 2024 was $46.0 million, up from $11.4 million in Q1 2023. Net loss for Q1 2024 was $26.5 million.
Ardelyx, Inc. will present additional data on XPHOZAH® (tenapanor) at the NKF 2024 Spring Clinical Meetings. XPHOZAH, a phosphate absorption inhibitor, is approved for CKD patients on dialysis. The drug offers a unique mechanism of action and will be discussed in various presentations during the event.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.